FDA Grants Orphan Designation to Investigational Idiopathic Pulmonary Fibrosis Treatment

Officials with the FDA granted orphan drug designation for Reviva Pharmaceuticals’ clinical stage drug candidate, RP5063 for treatment of idiopathic pulmonary fibrosis (IPF).

The drug has shown robust efficacy in highly recognized translational animal models proven to emulate pulmonary fibrosis in humans, significantly improving survival rate and reducing inflammatory cytokines and fibrosis in the lungs of bleomycin-induced pulmonary fibrosis animal model.

The findings indicate the potential for a clinically meaningful improvement and stabilization of lung function.

“Obtaining the Orphan Drug Designation is a significant regulatory milestone as well as a notable achievement for Reviva, since it validates the significant therapeutic potential of RP5063 for the treatment of IPF,” Laxminarayan Bhat, PHD, found, president, chief executive officer, Reviva, said in a statement.

The new chemical entity involves a novel mechanism of multimodal modulation of serotonin and dopamine signaling pathways. A potent inhibitor of the 5-HT2A/2B/7 receptors, RP5063 weakens functional changes in a series of well recognized translational animal models proven to emulate pulmonary fibrosis and pulmonary arterial hypertension.

Click to continue reading on MD Magazine. 

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by fibrosis and worsening lung function that predominantly affects individuals aged 60 years and older. IPF remains difficult to diagnose and manage, however, because of its unknown etiology, varied clinical course, associated comorbidities, and nonspecific respiratory symptoms. In fact, data show that when compared with age-, gender-, race-, and region-matched controls, patients with IPF have a 126% increased risk of emergency room visits and a 134% higher risk of hospitalization (per person-years, respectively). Consequently, IPF-related hospitalizations and acute exacerbations are associated with a high economic burden, accentuating the need for treatments that slow disease progression and improve patients’ quality of life. Two agents, nintedanib and pirfenidone, were FDA-approved for the treatment of IPF in 2014 and received conditional recommendations for use in the updated American Thoracic Society IPF Clinical Practice Guidelines. However, use of these medications is expected to significantly increase cost of care, considering each treatment regimen exceeds $90,000 annually. To optimize pharmacoeconomic outcomes, the use of these medications requires innovative strategies to manage costs associated with drug utilization and clinical management. Specialty pharmacies have emerged and continue to play a significant role in managing drugs with high acquisition costs through medication dispensing, disease management programs, and negotiating discounts and rebates to optimize patient care. As a result, it is critical that specialty pharmacists understand evolving treatment paradigms, the clinical course and evolution of disease, as well as the safe and appropriate use of medications in the management of IPF.
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease that is characterized by worsening dyspnea, declining lung function, nonspecific respiratory symptoms, a varied clinical course, as well as a host of comorbid conditions, making diagnosis and management challenging. Prior to the approval of pirfenidone and nintedanib in 2014, lung transplant and palliative care were the only options for management of IPF. With the addition of these 2 agents in the updated American Thoracic Society IPF Clinical Practice Guidelines with conditional recommendations, cost of care for IPF is expected to increase significantly. Pharmacists can play an important role for patients by knowing the nonpharmacologic and pharmacologic treatment options for patients with IPF, and providing education and guidance on the therapies to improve adherence.
This webinar will focus on pulmonary arterial hypertension (PAH) as a disease state as well as treatment guidelines and goals, which require a multidisciplinary approach from healthcare personnel. Health-system pharmacists’ involvement can enhance patient education and improve medication use as patients with PAH commonly use multiple treatments for the disease including supportive therapy, which significantly increases the chances of adverse effects and drug interactions. In addition, the options for treating symptoms of PAH have increased with several different drug classes and delivery routes available. This activity will highlight the information on the various therapeutic options to keep hospital pharmacists updated in order to provide the appropriate clinical guidance to the healthcare team.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.